A prospective trial to evaluate the safety and efficacy of CLS-1002 in patients with wet age-related macular degeneration
Phase of Trial: Phase I/II
Latest Information Update: 01 Aug 2016
At a glance
- Drugs Axitinib (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- 01 Aug 2016 According to a Clearside Biomedical media release, the company expects to submit an IND application to the US FDA in the second half of 2016.
- 28 Apr 2016 New trial record
- 26 Apr 2016 According to a Clearside Biomedical media release, the company has initiated IND-enabling studies for the treatment of wet AMD.